AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure [TheStreet.com]
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: TheStreet.com
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the randomization of the last participant was completed earlier this year for GenePHIT, its Phase 2 clinical trial of AB-1002, an investigational gene therapy being developed as a potential treatment for heart failure with reduced ejection fraction (HFrEF). “Heart failure is a major public health challenge and places a massive strain on healthcare systems around the world,” said Timothy D. Henry, MD, MSCAI, GenePHIT Principal Investigator and Steering Committee Member. “Prevalence is increasing, and the need for innovative therapies has never been greater. Completing enrollment in this trial brings us another step closer to evaluating a potential treatment strategy for heart failure with reduced ejection fraction.” GenePHIT includes 173 participants, and the completion of enrollment marks a significant milestone in the development of AB-1002, an i
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- What to know about the battle over lawsuits alleging that Roundup weedkiller can cause cancer 1 / 5 [Yahoo! Finance Canada]Yahoo! Finance Canada
- Federal health and environmental agencies to study microplastics and pharmaceuticals in drinking water [Los Angeles Times (CA)]Los Angeles Times
- Assessing Bayer (XTRA:BAYN) Valuation After Recent Share Price Rebound And Conflicting Fair Value Signals [Yahoo! Finance]Yahoo! Finance
- Booker urges Supreme Court to allow Roundup cancer lawsuits to proceed [CBS News]CBS News
- AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure [Yahoo! Finance]Yahoo! Finance